




Advancing a **leading**, global,
cancer diagnostics company

July 28, 2021



Safe harbor

This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts.

We aim to eradicate cancer and the suffering it causes through tests that help prevent cancer, detect it earlier, and guide treatment

Exact Sciences is a **leading**, global, advanced cancer diagnostics company

OUR PEOPLE

5,500+

employees

1,000+

person commercial team

450+

R&D employees

OUR TESTS

850k

people tested in 2Q21

cologuard®

oncotype^{DX}®

oncotype^{MAP}™

A LEADER IN DIAGNOSTICS



Broad and advanced capabilities, relationships, and foundation



Attacking cancer through early detection beginning with screening



Supporting largest markets across the continuum totaling \$60B+

We have the right team
and **culture** to succeed

Great
Place
To
Work.®

Certified

JUN 2021-JUN 2022

USA

TM


EXACT
SCIENCES
LABORATORIES

EXACT
SCIENCES
LABORATORIES

SCD PREP

Our foundation and strong brands help enable long-term revenue growth

Expected revenue growth 2018 to 2021
CAGR >55%



2021 revenue guidance by business


\$1.1B - \$1.125B
Screening

\$530M - \$540M
Precision Oncology

\$75M - \$80M
COVID testing

Note: Exact Sciences guidance for 2021 revenue as of July 28, 2021; 2020 includes full-year impact of Genomic Health acquisition

We have a **proven foundation** and **capabilities** in **diagnostics**




We have unmatched relationships across specialties

Sales team members	650	60	50	100	50	40
	Primary care	Gastroenterology	Women's health	Oncology	Urology	Health systems
Providers reached	50%	90%	30%	98%	40%	90%

Note: providers reached represents percent of total providers who have ordered in each specialty
Sources: med-pub.com/mms/web/AMA-SpecialtyByTOPS.pdf; Exact Sciences estimates

Detecting cancer earlier **at every stage,** starting with screening



We plan to lead 3 of the largest impact opportunities in diagnostics in the U.S.

 \$25B

multi-cancer screening

 \$18B

colorectal cancer screening

 \$15B

minimal residual disease
and recurrence monitoring

**EXACT
SCIENCES**

Thrive.
AN EXACT SCIENCES COMPANY

cologuard® 2.0
colon cancer blood test


 **ASHION** 

Note: Cologuard 2.0 and colon cancer blood test have not been cleared or approved by the FDA
Source: Exact Sciences estimates, includes U.S. markets only

SCREENING



Screening people **before they're symptomatic** is powerful



Colorectal cancer: solving the #2 cancer problem in the U.S.

#2

deadliest cancer
in men & women

53K

annual deaths

90%

survival if
caught early

\$18B

market opportunity

Sources: American Cancer Society Cancer Facts & Figures 2020, all figures annual;
Exact Sciences estimates

Cologuard is **a solution** to the colorectal cancer challenge



94%

Early-stage cancer sensitivity



Easy to use



No preparation



No time off work



Non-invasive



No sedation



24/7 customer support

Developed with



For adults 45 years or older and at average risk

Note: 94% for stage I and II cancers; 92% sensitivity overall, 87% specificity
Source: Imperiale TF et al., N Engl J Med (2014)

EXACT SCIENCES

Cologuard has several powerful growth opportunities

USPSTF
guideline support

19M

people ages
45-49

Expand current
market share

650

primary care field
and inside reps

Electronic
ordering

50%

goal by the
end of 2021

Retain current
Cologuard users

1 M+

rescreen eligible patients
by the end of 2021


Sources: U.S. Census data; Exact Sciences estimates

Setting the bar even higher with an **enhanced Cologuard**

Sensitivity: maintain **92%** for cancer, improve for pre-cancer

False positives: decrease by at least **30%**

Cost of goods and revenue: improve by **5-10%** per test



Note: Cologuard 2.0 has not been cleared or approved by the FDA – targets presented here are goals for test performance


Sources: Imperiale TF et al., N Engl J Med (2014); Exact Sciences estimates

Providing **another option to get screened** with a **blood test**

Provide another option for
46M unscreened patients,
FIT, and FOBT users

Make available through
current screening platform


Colon cancer **blood test**



Note: Colon cancer blood test has not been cleared or approved by the FDA

Sources: US Census data and CDC NHIS survey results as published in the CDC's MMWR between 2006 and 2017; Exact Sciences estimates

BLUE-C will support **two tests
with one prospective study**



BLUE-C

10,000 patients

Prospectively
collected stool and blood

FIT comparison

Note: Cologuard 2.0 and colon cancer blood test have not been cleared or approved by the FDA

BLOOD-BASED MULTI-CANCER SCREENING

**EXACT
SCIENCES**

Thrive.
AN EXACT SCIENCES COMPANY

**By combining the expertise of Exact Sciences and Thrive,
we believe we can bring this unique technology to patients faster**

Earlier detection could help solve the global cancer problem

#1

killer under
age 85

9.5M

total annual deaths

3%

of people over
age 50 have cancer

\$25B

U.S. market
opportunity

Sources: American Cancer Society Global Cancer Facts & Figures 4th Edition, 2018; Karwinski 1990, Burton 1998, Sens 2009; Exact Sciences estimates

Bringing together distinct approaches to lead multi-cancer screening



Mutation + protein

**EXACT
SCIENCES**

Methylation + protein

DETECT-A study results:

10k

patient prospective, interventional study

26

cancers found across 10 organs

65%

of detected cancers were earlier stage

Source: A. M. Lennon et al., Science (2020)

Rosemary had **stage I** ovarian cancer

“I never thought I would be the one. I have had no side effects from the surgery and am back to doing everything I did before.”



Designed to bring **better outcomes** to more patients

oncoguard[™] liver

3M

patients eligible
for testing




1 in 3

at-risk patients receive
recommended testing

Sources: Singal AG et al., J Hepatology (2020); 3M U.S. patients calculated using Census Bureau estimates of population and prevalence of cirrhosis as reported in Beste et al., Gastroenterology (2015)

EXACT SCIENCES



oncoguard[™] liver

PRECISION ONCOLOGY



Precision oncology is a strong platform for growth

Growth
platform

*oncotype*DX[®]

world-class
brand

Established
oncology presence

1.3M

cumulative patients
tested

Global
team

90


country
presence

Evidence
generation

300+

publications

Oncotype DX provides better **prognostic and therapy information** earlier



Breast cancer: addressing the #2 cancer killer in women

#2

deadliest cancer
among women

279k

annual U.S.
diagnoses

1/8

women will develop
breast cancer

\$1.2B

market opportunity

Sources: American Cancer Society Cancer Facts & Figures 2020, all figures annual;
Exact Sciences estimates

Oncotype DX is backed by significant, unmatched evidence

*oncotype*DX[®]
Breast Recurrence Score

TAILORx

10,000 women, 9 years

Early-stage, **node-negative**
breast cancer

**Definitive evidence Oncotype
predicts chemo benefit**

RxPONDER

5,000 women, up to 10 years

Early-stage, **node-positive**
breast cancer

**Supports Oncotype growth
in node-positive subset**

Sources: Sparano et al., N Engl J Med (2018); Geyer et al., NPJ Breast Cancer (2018);
Kalinsky K, Barlow WE, Meric-Bernstam F, et al. SWOG S1007 (RxPONDER). San Antonio Breast Cancer Symposium; 2020

Therapy selection: helping send patients to the **right treatment**

15%

of patients getting
comprehensive
testing today in U.S.

600k

patients in need
of testing in U.S.

\$3B

U.S. market
opportunity

Sources: A. Gondos et al., ASCO (2020); Exact Sciences estimates

Oncotype provides a **solid foundation** to enter therapy selection




Comprehensive genomic profiling to aid therapy selection in advanced cancer

Fast answers

High test completion rate

Broad target coverage

Building capabilities to catch **minimal residual disease and recurrence** earlier



Detecting minimal residual disease and recurrent cancer to **help patients move forward**

1.6M

patients in need
of testing in U.S.

10M

annual tests to support
patients in U.S.

\$15B

U.S. market
opportunity

Source: Exact Sciences estimates

TARDIS minimal residual disease test helps expand our **leadership in precision oncology**



Support entrance into and leadership in minimal residual disease testing



Access differentiated patient-specific approach with published data in breast cancer



Leverage precision oncology foundation to deliver better solution to patients navigating cancer

SCIENCE TRANSLATIONAL MEDICINE | RESEARCH ARTICLE

CANCER

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

Worldwide exclusive license to TGen's proprietary sequencing blood biopsy method

Note: TARDIS technology not yet available for commercial use

Ashion provides **high quality team and lab** to help lead precision oncology



CLIA-certified and CAP-accredited next generation sequencing lab



Whole exome, matched germline, and transcriptome sequencing capabilities



10-year collaboration with TGen and City of Hope to help extend leadership in precision oncology

Acquired PFS Genomics to provide **more critical answers** to breast cancer patients

Innovative, promising technology is intended to:



Identify which women with early-stage invasive breast cancer will benefit from radiotherapy



Allow for individualized radiotherapy treatment of early-stage breast cancer patients



Enhance Exact Sciences' ability to address key early-stage breast cancer treatment decisions

Journal of Clinical Oncology®

original reports

Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer

Martin Sjöström, MD, PhD^{1,2}; S. Laura Chang, PhD³; Nick Fishbane, MSc⁴; Elai Davicioni, PhD⁴; Shuang G. Zhao, MD⁵; Linda Hartman, PhD¹; Erik Holmberg, PhD⁶; Felix Y. Feng, MD⁷; Corey W. Speers, MD, PhD⁵; Lori J. Pierce, MD⁵; Per Malmström, MD, PhD^{1,2}; Märten Fernö, PhD¹; and Per Karlsson, MD, PhD⁶

PFS Genomics identified a gene expression signature to predict whether women treated with breast conserving surgery are likely to benefit from radiotherapy

Acquisitions are supporting innovation in precision oncology



May 2021

Technology addresses key breast cancer radiotherapy treatment decisions



Apr. 2021

Lab with whole exome sequencing capabilities



Jan. 2021

Exclusive license of targeted MRD sequencing method



Jan. 2021

Multi-cancer test, talented sequencing and bioinformatics team



Oct. 2020

Innovative methylation technology



Mar. 2020

Differentiated therapy selection test



Mar. 2020

Sequencing expertise



Nov. 2019


Powerful Oncotype brand and robust infrastructure



Oct. 2018

Superior blood tubes to preserve more DNA

Detecting cancer earlier at every stage



cologuard[®]

oncoguard[™] liver

oncotype[®] DX[®]

oncotype[®] MAP[™]

Thrive.
AN EXACT SCIENCES COMPANY
base
GENOMICS

Genomic Health
LIFE, CHANGING.
PFS GENOMICS

Biomātrica
base
GENOMICS

viomics
TARDIS

Paradigm
ASHION[®]

Second quarter 2021 financials

	Q2 2021	Q2 2020
Revenue	\$435M	\$269M
Screening	\$264M*	\$131M
Precision Oncology	\$138M	\$103M
COVID testing	\$33M	\$35M
Gross margin	69%	63%
Non-GAAP gross margin	74%	71%
Adjusted EBITDA	-\$27M	-\$5M
Ending cash balance	\$1,308M	\$1,223M

*Screening revenue included a one-time downward adjustment of \$12.1 million related to the passing of the contractual deadline to submit claims for previously completed Cologuard tests

Non-GAAP gross margin excludes amortization of acquisition-related intangibles

Please refer to the table in the associated press release labeled EBITDA and Adjusted EBITDA Reconciliations

Ending cash balance includes cash, cash equivalents and marketable securities; Revenue totals do not foot due to rounding

We aim to eradicate cancer and the suffering it causes through tests that help prevent cancer, detect it earlier, and guide treatment